Stryker's Strategic Moves Impress Analysts, Spine Implant Sale and NARI Deal Set to Drive Future Growth

Wall Street analysts rerated Stryker Corp SYK Wednesday after the company’s fourth-quarter print.Stryker reported quarterly earnings of $4.01 per share, which beat the analyst consensus estimate of $3.87. The company reported quarterly sales of $6.44 billion, up by 10.7%, which beat the analyst consensus estimate of $6.36 billion.Also Read: Nasdaq Touts 10% Revenue Growth In Q4, Sets 2025 Expense And Tax GuidanceSeveral analysts rerated the stock:Stifel analyst Rick Wise maintained Stryker with a Buy and ra ...